Federico Pulido
A5000764626- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Tuberculosis Research and Epidemiology
- Hepatitis B Virus Studies
- HIV, Drug Use, Sexual Risk
- HIV/AIDS oral health manifestations
- Chronic Lymphocytic Leukemia Research
- Cytomegalovirus and herpesvirus research
- Syphilis Diagnosis and Treatment
- Research on Leishmaniasis Studies
- Liver Disease and Transplantation
- Biochemical and Molecular Research
- Immunodeficiency and Autoimmune Disorders
- Hemophilia Treatment and Research
- Diabetes and associated disorders
- COVID-19 Clinical Research Studies
- Viral-associated cancers and disorders
- Pneumonia and Respiratory Infections
- Diagnosis and treatment of tuberculosis
- Sex work and related issues
Hospital Universitario 12 De Octubre
2016-2025
Universidad Complutense de Madrid
2010-2025
Centro de Investigación Biomédica en Red
2022-2025
Instituto de Salud Carlos III
1997-2024
Research Institute Hospital 12 de Octubre
2011-2023
Hospital Universitario HM Madrid
2021
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos
2021
Hospital Universitario Infanta Leonor
2019
Instituto de Investigación Biosanitaria de Granada
2019
Hospital General Universitario de Elche
2018
Background The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major updates every two years. Guideline highlights 2019 were extended a new section focusing on drug–drug interactions and other prescribing issues in people living (PLWH). recommendations for treatment‐naïve PLWH updated four preferred regimens favouring unboosted integrase inhibitors. A two‐drug regimen dolutegravir lamivudine, three‐drug including doravirine also added to the...
In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.Two hundred fifty-six patients with HIV RNA less than 50 copies/ml for over 24 weeks on current antiretrovirals [non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (43%), or protease inhibitor-based (57%)], switched 800/100 mg once daily, either as (n = 127) nucleoside inhibitors (NRTIs) 129). Treatment failure was defined...
Background. Sustained virological response (SVR) after therapy with interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected human immunodeficiency virus (HIV) hepatitis C (HCV). We assessed the effect of SVR on HIV progression not related to liver disease.
Background: Prior attempts to reduce the number of drugs needed maintain viral suppression in patients with suppressed HIV replication while receiving three antiretroviral have been unsuccessful. Methods: In 205 on lopinavir-ritonavir and two nucleosides, this randomized, open-label, non-inferiority clinical trial compared strategies continuation triple therapy versus monotherapy followed by reinduction nucleosides if virological rebound occurred without genotypic resistance...
Objective: To evaluate the efficacy and safety/tolerability of dolutegravir (DTG, S/GSK1349572), a potent inhibitor HIV integrase, through full 96 weeks SPRING-1 study. Design: ING112276 (SPRING-1) was 96-week, randomized, partially blinded, phase IIb dose-ranging Methods: Treatment-naive adults with received DTG 10, 25, or 50 mg once daily efavirenz (EFV) 600 (control arm) combined investigator-selected dual nucleos(t)ide reverse transcriptase backbone regimen (tenofovir/emtricitabine...
Alternative combinations of antiretrovirals (ARVs) are desired to increase treatment options for HIV-infected patients. PROGRESS was a randomized, open-label, 96-week pilot study comparing regimen lopinavir/ritonavir (LPV/r) 400/100 mg twice daily in combination with either raltegravir (RAL) 400 or tenofovir/emtricitabine (TDF/FTC) 300/200 once ARV-naive adults. A total 206 subjects were randomized and treated (LPV/r+RAL, N=101; LPV/r+TDF/FTC, N=105). Demographics baseline characteristics...
Challenges with adherence to daily oral antiretroviral therapy (ART) among people living HIV (PLHIV) have stimulated development of injectable long-acting (LA) regimens. We conducted 39 in-depth interviews participants and providers in a Phase IIb study (LATTE-2) evaluating an LA regimen the U.S. Spain. Interviews exploring participant provider attitudes experiences versus ART were audiotaped, transcribed analyzed using thematic content analysis. Participants described convenience injections...
Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared triple plus 2 nucleos(t)ides for maintenance human immunodeficiency virus type 1 (HIV-1) suppression.This a multicenter, open-label, trial (margin 12%). Patients HIV-1 RNA <50 copies/mL 6 months or longer on (tenofovir disoproxil fumarate emtricitabine abacavir lamivudine) no resistance were randomized continue (n = 128) switch 129). The primary endpoint proportion...
This study evaluated maintenance with lopinavir/ritonavir monotherapy vs. continuing and 2 nucleosides in HIV-infected patients suppressed HIV replication.Randomized, controlled, open-label, multicenter, pilot clinical trial.Adult were eligible if they had no history of virologic failure while receiving a protease inhibitor, + (400/100 mg b.i.d.) for >1 month maintained serum RNA <50 copies/mL >6 months prior to enrollment.Forty-two randomly assigned 1:1 continue or stop the nucleosides. At...
To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared stavudine in HIV-infected antiretroviral-naive patients.This was a prospective, randomized, open trial, stratified by viral load CD4 cell count, conducted January 2001 to July 2004. Two hundred thirty-seven adult patients HIV infection initiating antiretroviral therapy were assigned receive (n = 115) or 122), both combined lamivudine efavirenz. The primary endpoint the proportion of lipoatrophy...
The OK04 trial has shown that 48 weeks of lopinavir-ritonavir monotherapy with reintroduction nucleosides as needed was noninferior to continuation triple therapy 2 and in patients prior stable suppression. However, it is still uncertain if this experimental strategy can maintain suppression the long term.Patients entered noninferiority (upper limit 95% confidence interval: +12%) no history virological failure while receiving a protease inhibitor plus lopinavir/ritonavir, HIV RNA <50 copies...
Objective: To assess the prevalence and factors associated with significant hepatic steatosis (SHS, involving ≥10% hepatocytes) in HIV-infected patients. Design: A prospective, cross-sectional study. Methods: Five hundred five patients were included this All underwent a transient elastography examination controlled attenuation parameter (CAP). SHS was defined using previously identified CAP cut-off of 238 dB/m. We analysed associations between demographics, metabolic data, coinfections drug...
ObjectivesTo analyze the impact of late presentation (LP) on overall mortality and causes death describe LP trends risk factors (2004–2013).MethodsCox models logistic regression were used to data from a nation-wide cohort in Spain. is defined as being diagnosed when CD4 < 350 cells/ml or AIDS.ResultsOf 7165 new HIV diagnoses, 46.9% (CI95%:45.7–48.0) LP, 240 patients died.First-year was highest (aHRLP.vs.nLP = 10.3[CI95%:5.5–19.3]); between 1 4 years post-diagnosis, aHRLP.vs.nLP 1.9(1.2–3.0);...
Abstract The aim of this transversal study was to describe the virological and immunological features HIV-infected youths transferred from pediatric adult care units since 1997 vs. non-transferred patients Madrid Cohort children adolescents in Spain. We included 106 184 under clinical follow-up 17 public hospitals by end December 2017. Virological outcomes were compared patients. ART drug resistance mutations HIV-variants analyzed all subjects with available pol genotypes and/or genotypic...
We report the 48-week results of an ongoing study to assess efficacy and safety switching older people with HIV bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). This was a 96-week, phase 3b, open-label, single-arm (GS-US-380-4449; NCT03405935). Virologically suppressed individuals aged ≥ 65 years receiving elvitegravir/cobicistat/emtricitabine/tenofovir or tenofovir disoproxil fumarate-based regimen were switched B/F/TAF. Primary endpoint percentage participants HIV-1 RNA < 50...
Abstract Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive virologically suppressed treatment-experienced individuals in multicentre cohort Spanish HIV/AIDS Research Network (CoRIS) during years 2018–2021. Methods We used multivariable regression models to compare viral suppression (VS) [HIV RNA load (VL) &lt;50 copies/mL] change CD4 cell counts at 24 48 (±12) weeks after initiation with dolutegravir/lamivudine or other...
BackgroundWhile a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear.MethodsWe analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 and year two of antiretroviral therapy (ART) could predict serious non-AIDS (SNAEs) next five years. These included major adverse cardiovascular events, non-AIDS-defining malignancies, non-accidental deaths. We used pooled logistic...